Navigation Links
Are New Chemo Treatments Cost-Effective?
Date:3/16/2010

Drug advances extend lives, but one study puts cost per life-year gained at about $66,200

TUESDAY, March 16 (HealthDay News) -- New chemotherapy agents for metastatic colon cancer improve patient survival but are costly, says a new study.

Researchers at Emory University in Atlanta analyzed data from 4,665 patients, aged 66 and older, diagnosed with metastatic colon cancer between 1995 and 2005. Compared to those who received older chemotherapy agents, patients who received one or more of the six chemotherapy agents approved in the United States between 1996 and 2004 lived an average of 6.8 months longer.

That increase in survival was associated with a lifetime cost increase of $37,100, which equates to $66,200 per year of life gained. After they made additional adjustments, the researchers calculated that the cost for each quality-adjusted life-year (a year of life in perfect health) gained was $99,100.

The study was published in the March 16 online edition of the journal Archives of Internal Medicine.

"New chemotherapeutic agents for colorectal cancer have been singled out as examples of high-cost/low-value medical care; no doubt they are the types of therapies that would receive close scrutiny if Medicare and other payers were to consider cost-effectiveness in coverage decisions," wrote David H. Howard and colleagues.

"Our estimate of the cost per quality-adjusted life-year gained, $100,000, is below most estimates of the willingness to pay for a life-year. However, continuation of Medicare's open-ended coverage policy for new chemotherapeutic agents and other expensive technologies will prove difficult to sustain as costs for the program continue to rise," they concluded.

More information

The American Cancer Society has more about colorectal cancer.



-- Robert Preidt



SOURCE: JAMA/Archives journals, news release, March 16, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Older Colon Cancer Patients Less Likely to Get Chemo
2. Study evaluates costs and benefits of new chemotherapy drugs
3. Scientists identify microRNA as possible cause of chemotherapy resistance
4. Roche/Genentech/Chugais Herceptin as an Add-On to Standard Chemotherapy Will Become Decision Resources Clinical Gold Standard in 2013 for the Treatment Of Gastric Cancer
5. New developments in nanotechnology tackle the 2 biggest problems associated with chemotherapy
6. Patients with resectable esophageal adenocarcinoma benefit from neoadjuvant chemoradiotherapy
7. Breast cancer multigene test helping patients avoid chemotherapy
8. Stem Cells Might Reverse Heart Damage From Chemo
9. Herb May Counter Liver Damage From Chemo
10. Mayo Clinic researchers say breast cancer survival improves Herceptin used with chemotherapy
11. Chemo With Herceptin May Be Best for Some Breast Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... WASHINGTON, DC (PRWEB) , ... March 30, 2017 ... ... Truth. , On the eve of Autism Awareness Month, representatives from Organic ... Center, World Mercury Project, Focus For Health Foundation, A Voice for Choice, Moms ...
(Date:3/30/2017)... ... March 30, 2017 , ... Nutrition Education ... and Dietetics (AND), will join nonprofit Seafood Nutrition Partnership (SNP) in presenting “Eating ... designed to help nutrition educators and students inform consumers about the health benefits ...
(Date:3/30/2017)... ... March 30, 2017 , ... ... letter to President Trump expressing their support for an independent Vaccine Safety Commission. ... scientists and one medical journalist, will hold a press conference at 9:00 ...
(Date:3/29/2017)... WI (PRWEB) , ... March 29, 2017 , ... ARI ... its exclusive provider of co-op eligible dealer websites for its network of more than ... of professional landscaping and agricultural equipment including rotary and flail mowers and cutters, rear ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... professional squash, announced it has enlisted New York City-based sports and entertainment marketing ... develop and procure sponsorship opportunities for the Professional Squash Association (PSA), which includes ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... EAST HANOVER, N.J. , March 29, 2017 ... and Drug Administration (FDA) has accepted the company,s ... review for CTL019 (tisagenlecleucel-T), an investigational chimeric antigen ... refractory (r/r) pediatric and young adult patients with ... first BLA submission by Novartis for a CAR-T. ...
(Date:3/29/2017)... 2017 Research and Markets has announced ... - 2025" report to their offering. ... The global orthopedic ... by 2025. Increasing geriatric population prone to orthopedic diseases is ... systems over the forecast period. Osteoarthritis and osteoporosis are most ...
(Date:3/29/2017)... WALNUT CREEK, Calif. , Mar 29, 2017 ... tissue-sparing, cervical-fusion technology, announced the addition of two ... Scott Lynch has joined the company to ... is assuming International leadership.  Together, Mr. Lynch and ... industry experience.  Mr. Lynch joins ...
Breaking Medicine Technology: